Accessing the European Pharma Market: becoming a MAH through dossier adaptation (II)

The European pharma market is becoming more competitive and accessible through its effort to adopt globally acknowledged standards and requirements, it is not surprising the increasing interest of investors to this appealing market. When a non-European company is considering investing in EU business opportunities different strategies may be implemented depending on the company needs. One…

Accessing the European Pharma Market: becoming a MAH through dossier acquisition.

  Positioned as the second largest pharmaceutical market in the world and showing a steady and extensive growth pattern, Europe’s pharma market is becoming increasingly attractive, but accessing this market implies both regulatory and technical requirements, so different strategies need to be considered to ensure cost-effectiveness. One of the options available for companies seeking to…